Profile data is unavailable for this security.
About the company
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
- Revenue in USD (TTM)84.50m
- Net income in USD-21.67m
- Incorporated2015
- Employees100.00
- LocationY-mAbs Therapeutics Inc230 PARK AVENUE, SUITE 3350NEW YORK 10169United StatesUSA
- Phone+1 (212) 847-9841
- Fax+1 (302) 655-5049
- Websitehttps://www.ymabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astria Therapeutics Inc | 0.00 | -81.63m | 502.45m | 59.00 | -- | 1.84 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -101.76m | 504.99m | 102.00 | -- | 1.54 | -- | -- | -1.81 | -1.81 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -35.25 | -33.92 | -37.18 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
| SNDL Inc | 658.39m | -99.36m | 507.96m | 2.52k | -- | 0.5771 | -- | 0.7715 | -0.3795 | -0.3883 | 2.52 | 3.38 | 0.5855 | 4.67 | 33.35 | 261,682.80 | -9.19 | -24.44 | -9.95 | -27.94 | 24.97 | 22.49 | -15.69 | -62.17 | 2.86 | -83.91 | 0.1157 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 509.21m | 118.00 | -- | 4.71 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| Replimune Group Inc | 0.00 | -215.79m | 513.74m | 331.00 | -- | 1.37 | -- | -- | -3.24 | -3.24 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -38.05 | -29.08 | -40.71 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1593 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Cabaletta Bio Inc | 0.00 | -76.87m | 514.63m | 118.00 | -- | 2.32 | -- | -- | -1.73 | -1.73 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -44.70 | -33.76 | -48.55 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Erasca Inc | 0.00 | -126.86m | 516.42m | 126.00 | -- | 1.14 | -- | -- | -0.8423 | -0.8423 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -30.29 | -- | -32.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 522.64m | 100.00 | -- | 5.27 | -- | 6.19 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.34m | -72.21m | 523.10m | 25.00 | -- | -- | -- | 391.54 | -0.0629 | -0.0629 | 0.0012 | -0.0447 | 0.0435 | -- | -- | 53,440.00 | -228.72 | -381.58 | -- | -- | -- | -- | -5,258.91 | -6,479.25 | -- | -10.49 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Celcuity Inc | 0.00 | -73.45m | 527.57m | 55.00 | -- | 3.46 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -91.06m | 530.35m | 66.00 | -- | 2.24 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Entrada Therapeutics Inc | 162.87m | 23.49m | 532.72m | 160.00 | 25.16 | 1.97 | 19.89 | 3.27 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 535.40m | 19.00 | -- | 5.43 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| Heron Therapeutics Inc | 132.10m | -80.95m | 542.35m | 126.00 | -- | -- | -- | 4.11 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 545.85m | 380.00 | -- | 7.37 | -- | 3.51 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Third Harmonic Bio Inc | 0.00 | -29.60m | 545.86m | 31.00 | -- | 2.04 | -- | -- | -0.7475 | -0.7475 | 0.00 | 6.55 | 0.00 | -- | -- | 0.00 | -10.53 | -- | -10.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Y-mAbs Therapeutics Inc's reporting currency: US Dollar USD
38.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 3.30m | 7.52% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.54m | 5.78% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 2.23m | 5.09% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.01m | 4.59% |
| Polar Capital LLPas of 31 Mar 2024 | 1.83m | 4.17% |
| Point72 Asset Management LPas of 31 Mar 2024 | 1.55m | 3.53% |
| D. E. Shaw & Co. LPas of 31 Mar 2024 | 1.07m | 2.43% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 751.07k | 1.71% |
| Pictet Asset Management SAas of 31 Mar 2024 | 746.10k | 1.70% |
| Geode Capital Management LLCas of 31 Mar 2024 | 742.75k | 1.69% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
